From Medscape Oncology

Coverage from the

Genitourinary Cancers Symposium (GUCS) 2017

February 16 - 18, 2017; Orlando, Florida

February 16 - 18, 2017 Orlando, Florida

GUCS First Look at Combo With Immunotherapy in Untreated mRCC
Medscape Medical News, February 27, 2017
GUCS Active Surveillance for Metastatic Cancer? Just This One
Medscape Medical News, February 23, 2017
In Sunny LA, Prostate Cancer Patients Just Walk Away
Medscape Medical News, February 20, 2017
GUCS In NEJM: Practice-Changing Trial in Urothelial Cancer
Medscape Medical News, February 17, 2017

GUCS Take With Food, Cut $9000 Prostate Cancer Pill Cost by 75%
Medscape Medical News, February 17, 2017
GUCS Some Stop Immunotherapy, Still Have Controlled Cancer
Medscape Medical News, February 14, 2017
GUCS Blood Test Instead of Biopsy for Metastatic Prostate Cancer
Medscape Medical News, February 14, 2017
GUCS Antibiotics May Impair Cancer Immunotherapy
Medscape Medical News, February 13, 2017

Conference News

GUCS Take With Food, Cut $9000 Prostate Cancer Pill Cost by 75% As with so many newer cancer drugs, abiraterone, for advanced castration-resistant prostate cancer, is very expensive. Here's a tip that may reduce cost greatly and does not appear to hurt efficacy.
Medscape Medical News, February 17, 2017
GUCS Some Stop Immunotherapy, Still Have Controlled Cancer In a small study of patients with advanced renal cell carcinoma, nearly half had durable responses after discontinuing checkpoint inhibitors because of toxicities.
Medscape Medical News, February 14, 2017
GUCS Antibiotics May Impair Cancer Immunotherapy Antibiotic use in the month before a metastatic kidney cancer patient starts immunotherapy may reduce efficacy, but new results need prospective confirmation.
Medscape Medical News, February 13, 2017

Popular News From GUCS 2016

'Liquid Biopsy' May Help Guide Treatment in Prostate Cancer Single CTC morphology, protein, and genomic characterization are feasible and can be used to assess tumor heterogeneity and potentially guide treatment decisions.
Medscape Medical News, Jan 5, 2016
'Bipolar' Therapy: New Twist in Advanced Prostate Cancer Challenging current notions, exposing prostate cancer cells alternately to very high and very low levels of testosterone may have clinical benefit and improve quality of life.
Medscape Medical News, Jan 13, 2016
Which Kidney Cancer Drug on Progression? Surprising Answers Although cabozantinib has shown the best progression-free survival ever seen, nivolumab improves overall survival and has fewer adverse events.
Medscape Medical News, Jan 5, 2016

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Previous Coverage

Related Resources

Genitourinary, Prostate Cancer News & Perspectives